

KEY POINTS

- Many women who have given birth during the coronavirus disease 2019 pandemic have received restricted postnatal care due to health policies that aim to reduce the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission.
- There is limited risk of transmission between mother and infant during pregnancy, birth, breastfeeding, or rooming-in when public health hygiene measures are followed.
- Breastfeeding may confer protection against SARS-CoV-2 via secretory immunoglobulin A antibodies transferred in human milk from both infected mothers and after vaccination.
- Although pregnant and breastfeeding women are at increased risk of ill health from SARS-CoV-2, they are also at significant risk of poor mental health, and wellbeing which may further affect their breastfeeding choices.
- Supporting breastfeeding women with continued in-person and digital health services is essential as the pandemic continues.

implemented to prevent mother-to-infant transmission early in the pandemic. Underpinned by scant evidence, many policies negatively impacted pregnant and breastfeeding women with suspected infection, typically requiring them to labour without extra support people and be separated from their newborn at birth. Partners were restricted from visiting the hospital, and women were discharged early. Some hospitals extended these policies to all birthing women. Changes to maternity care occurred in high, low, and middle-income countries (LMIC) alike. In a survey assessing frontline workers' experience of the maternal and newborn services during the pandemic, health professionals across 81 countries highlighted that woman experienced reduced access and frequency of antenatal services, in-person visits, and support people allowed after birth. Telemedicine was also more frequently utilized, although women living in LMICs reported the highest barrier to accessing this service [2[■],3]. Similar findings were shown in European-based hospital surveys of health professionals, reporting a shorter postpartum stay, and limited parental access to infants in neonatal intensive care (NICU) [1[■]]. Other studies have shown that families received conflicting information on whether direct breastfeeding was safe. Once at home, breastfeeding women experienced reduced access to lactation and mental health support [4[■],5,6]. The combination of restrictive policies, misinformation, and lack

of evidence complicated the provision of human milk (HM) and maternal-infant bonding during the early months of the pandemic [7[■]].

Such practices contrast the relatively early recommendations adopted by the World Health Organization and others to protect and promote continued breastfeeding during the pandemic [8–10]. Global recommendations emphasized the importance of establishing breastfeeding, rooming-in, and skin-to-skin contact [8,9]. Mothers who are SARS-Cov-2 positive and are well enough should continue breastfeeding or expressing milk, rooming-in, and caring for their newborn while adhering to appropriate infection-control measures such as hand hygiene and wearing a mask [9]. Infection control practices effectively reduce the transmission of SARS-Cov-2. In a US-based study, there were no cases of maternal-to-infant transmission after 14 days amongst families who implemented appropriate infection control measures while rooming-in or breastfeeding [11[■]]. Findings from longitudinal studies in the UK [12] and Israel [13] have reaffirmed that since neonatal infection is unlikely, SARS-Cov-2 positive mothers should not be separated from their infants.

CORONAVIRUS DISEASE 2019 TRANSMISSION FOR PREGNANT AND BREASTFEEDING WOMEN

Pregnant and recently pregnant women are more likely to get severely ill from COVID-19 than non-pregnant women [14,15[■]]. Pregnancy causes changes in the body that make it easier to become unwell from respiratory viruses like SARS-Cov-2. These changes can persist after birth, potentially heightening the risk for breastfeeding women. Indeed, an analysis of over 400 000 women with symptomatic SARS-Cov-2 infection showed that pregnant women had a three-fold increased risk of being placed in intensive care, 2.9 times increased risk of mechanical ventilation, and 1.7 increased risk of death compared their nonpregnant counterparts [15[■]]. Pregnant women with severe infections are also at increased risk of preterm birth, pregnancy loss, and neonatal morbidity [14,16[■]].

Although pregnant women are at greater risk of infection, vertical transmission of the virus from mother to infant is rare during pregnancy, birth, and lactation [5]. Registry data from more than 9500 births in the United States suggest vertical transmission after delivery occurs in approximately 2% of infants born to SARS-Cov-2 positive mothers [10]. Other data support these findings reporting either no transmission [17,18] or single cases of probable transplacental or intrauterine transmission during

pregnancy and labour, respectively [14,19–21]. No reports of transmission have been demonstrated via HM [17,22[■],23]. Although viral RNA has been isolated in some HM samples of SARS-Cov-2 positive mothers, none contained replicant-capable SARS-Cov-2 [22[■],23–26,27[■]].

SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPECIFIC SECRETORY IMMUNOGLOBULIN A PROTECTION IN HUMAN MILK

Strong evidence shows that antibodies to SARS-Cov-2 isolated in HM have an immunological response against the virus. After maternal SARS-Cov-2 infection, antibody isotypes measured in HM include sIgA/IgA, secretory immunoglobulin M (sIgM)/IgM, and secretory immunoglobulin G (sIgG)/IgG [27[■],28,29[■],30]. The most abundant sIgA shows robust neutralizing activity specific to SARS-Cov-2 [27[■],28,29[■],30]. HM samples of infected women have demonstrated that sIgA and IgG activity persists for up to 5 months postinfection in milk and maternal serum, respectively. While sIgA levels in milk generally declined slightly over time, maternal serum samples of IgG were unchanged [3]. SARS-Cov-2 specific sIgA was not detected in several samples of mothers who tested positive for SARS-Cov-2 but were asymptomatic, indicating they had a low viral load. Additional studies have shown SARS-Cov-2 specific IgG in serum samples of lactating mothers up to 8 months postinfection [25,31].

HM sIgA protects against pathogens that can cause respiratory and gastrointestinal illness by neutralizing viruses and preventing bacterial adhesion to the infant's mucosal surfaces [32]. Therefore, it is highly likely that after maternal infection, breastfeeding offers a level of passive immunity to the infant through SARS-CoV-2 specific sIgA [33[■]]. Whether this protection reduces SARS-CoV-2 infection through vertical transmission or direct or indirect contact with others is unclear. Evidence from enteric [34] and influenza viruses suggests so [35]; however longitudinal observational studies of SARS-CoV-2 positive breastfeeding women and their infants are required to elucidate the specific role of SARS-CoV-2 sIgA in infant immune protection.

CONTINUED FEEDING IN THE NEONATAL INTENSIVE CARE SETTING

An important consideration is breastfeeding and feeding expressed milk to hospitalized sick and pre-term infants during the pandemic. Studies show when active SARS-CoV-2 is added to HM, holder pasteurization (62.5°C for 30 min) inactivates the

virus. Therefore, feeding holder pasteurized donor HM can be considered safe in NICU [22[■],28,36]. In this notion, the continuation of breastfeeding and skin-to-skin or kangaroo mother care (KMC) during the pandemic also extends to the NICU setting. Data show that KMC and breastfeeding during COVID-19 are essential to neonatal survival, particularly in LMIC. Statistical modelling of LMICs revealed that at a hypothetical vertical transmission rate of 10%, universal KMC (99% coverage, including skin-to-skin care and breastfeeding) for infants weighing <2000 g would benefit infant survival 650 times that of the mortality risk from SARS-CoV-2 infection. This strategy could save an estimated 125 680 neonatal lives over 12 months of the pandemic [37[■]]. With COVID-19 hygiene measures implemented, feeding fresh mother's own milk or pasteurized donor milk for sick infants in the NICU is safe.

SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 VACCINATION DURING LACTATION

Although more than fifty SARS-CoV-2 vaccine candidates reached clinical trial stages, none were initially inclusive of pregnant or breastfeeding populations [38], resulting in a substantial knowledge deficit concerning vaccination safety for these women [39]. Once vaccinations became available, national bodies neither recommended nor excluded vaccination during pregnancy and lactation, leaving women to decide on the COVID-19 immunization based on their individual health circumstances. Many women were confused by mixed messages from their health providers and respective governments and hesitant to receive the vaccination. Since then, international evidence has confirmed the safety and efficacy of vaccination against SARS-CoV-2, and it has become universally recommended for pregnant and breastfeeding women.

Multiple efficacy-based studies have demonstrated that mRNA-based vaccination of pregnant and breastfeeding women results in the secretion of SARS-CoV-2 specific neutralizing activity of IgA and IgG provided via the placenta and HM [40,41[■],42[■],43–45]. Minimal adverse effects of mRNA vaccines and no serious adverse events have been reported for the breastfeeding mother or infant. A small percentage of women reported a transient reduction in their milk production following the first dose, which returned to prevaccination levels within 72 h [46]. Additionally, safety data and prospective registries following women vaccinated in pregnancy have found no adverse outcomes for the pregnancy or foetus [47,48]. The overwhelming evidence indicates that pregnant and breastfeeding

women should continue to be routinely offered vaccination against SARS-CoV-2, which not only protects the mother but may also confer protection to the infant via the transfer of antibodies in HM. The duration of the antibody response to SARS-CoV-2 in HM after vaccination is yet to be clarified. Interestingly, women breastfeeding longer than 24 months appear to have higher immunoglobulin concentrations in response to vaccination than women who breastfeed for shorter periods [43].

EFFECT OF CORONAVIRUS DISEASE 2019 ON MATERNAL WELLBEING

Despite the abundance of evidence supporting breastfeeding, lactation and perinatal mental health support must be prioritized during the pandemic. New mothers are already at increased risk of mental health issues. Postpartum physiological and psychological changes affect maternal mental health and increase the risk of psychological stress, anxiety, and depression. Before the pandemic, 10–20% of perinatal women experienced mental health problems. Research during the COVID-19 pandemic has since shown exceptional rates of anxiety and depression amongst pregnant and postpartum women across Europe, North America, China, and Australia [49,50,51[■],52,53]. Such findings highlight the need for clinical protocols and resources to ensure screening and treatment for perinatal anxiety, depression, and stress during the pandemic.

Some mothers have stated that the pandemic has triggered positive changes, including less pressure and more partner support to continue breastfeeding [50,51[■],54]. Others have highlighted that reduced access to support has caused their early weaning [51[■]]. Individual circumstances and the types of restrictions implemented may also play a role in women's breastfeeding choices. For instance, Australian and New Zealand women that experienced lockdown for more extended periods of their pregnancy were more likely to cease exclusive breastfeeding [54]. They also had poorer mental health outcomes, as did women living in regions with higher COVID-19 infection rates [54]. Similarly, in a sample of UK women [51[■]], 41% felt that breastfeeding was protected. In comparison, 27% struggled to get support, with some citing the pandemic as their reason for stopping breastfeeding earlier than planned. This occurred if they gave birth during lockdowns, they were living in challenging circumstances, with lower levels of education, or from minority ethnic backgrounds. Such evidence highlights that we must consider the mothers' personal experience and home life during the pandemic and how it may affect their breastfeeding

choices differently when individualizing lactation care [55].

PERINATAL SUPPORT MOVING FORWARD IN THE PANDEMIC

The importance of support on maternal wellbeing has been strongly emphasized both before and during the pandemic [53]. During the pandemic, low scores of family function have been associated with poorer mental wellbeing in Australian breastfeeding women [54]. Data from the US has reinforced the importance of comprehensive family networks and breastfeeding support services during COVID-19 [6]. Mothers highly valued in-person emotional support via family and peer networks and informational support via in-person lactation services. Lockdowns caused reductions in all forms of in-person support, resulting in increased stress and smaller social support networks amongst mothers. Therefore, it remains critical that in-person community efforts are maintained for maternal-infant health visits. Furthermore, determining how best to provide virtual support is required when in-person visits are impossible [6]. New, evidence-based, and forward-thinking support measures are needed to ensure these women have continued access to support.

Several strategies have been proposed to help women across different stages in pregnancy and lactation during the pandemic (Table 1) [7[■]]. Lactation telehealth services, including digital applications, telephone, mobile phone, and video conferencing, have been demonstrated to be equally effective and feasible in higher and lower-income populations. However, it is unclear if telehealth lactation programs are consistently associated with improvements in breastfeeding rates. Understanding if telehealth services versus standard in-person services support long-term breastfeeding outcomes requires further investigation [56].

Online antenatal breastfeeding education has a similar potential to become accredited and standardized [7[■]]. During the COVID-19 pandemic, many face-to-face programs were either cancelled or rapidly brought online. It has become clear that women should have access to breastfeeding education across all delivery modes to suit their needs, including online prerecorded modules, smartphone applications, and in-person training whenever possible [7[■]]. Furthermore, validating and testing online education modules may be prudent in ensuring the health professionals can effectively teach all practical components of birthing and lactation online.

In the case of maternal and infant separation, while ensuring physical visitation is critical,

Table 1. Future lactation services, benefits, risk and requirements

| Lactation support strategies | Method | Benefits | Risks | Future requirements |
|----------------------------------|---|--|--|--|
| Telehealth | Application, telephone, mobile, video conferencing | Increased access to lactation care during outbreaks, and for people living in rural locations | Unregulated online clinical IBCLC practice across countries | Implemented into standardized IBCLC and lactation training models |
| Online Antenatal education | Application, telephone, mobile, video conferencing | Opportunity to receive antenatal education with low risk of transmission | Practical topics concerning birthing and breastfeeding require adaption to online models of teaching | Accreditation and evaluation of online courses |
| Connected NICU services | Application, mobile, video conferencing | Increased visual contact between families and infant, access to nurse and infant health charts | Reduction in visits if able to virtually feel connected | Testing user requirements (NICU parents and health workers) before app development |
| Contactless milk delivery | Application, mobile, QR scanning, comprehensive milk drop off and milk bank team system | Low transmission risk when dropping milk to the NICU | Costly infrastructure to set up | Model milk bank/NICU test set-ups to demonstrate the feasibility |
| Supportive network bubbles | Rapid antigen testing, vaccination to ensure safe access to services | Low transmission risk while ensuring social connections and health services maintained | Difficult to enforce without local government policy | Financial investment and lobbying local governments for support |
| Comprehensive wellbeing services | Mental health services, social welfare, and access to family leave | Ensures holistic care is accessible for new families to continue breastfeeding | Requires government policy and significant financial investment | Lobbying national governments to financially support maternity and family leave |

IBCLC, international board certified lactation consultant. NICU, neonatal intensive care unit.

connecting mothers, families and their infants virtually is also possible in some settings. For example, low transmission risk rooms in the NICU setting, such as dedicated visitation rooms or single rooms, maybe beneficial to minimize the exposure between visitors. Smartphone applications that may enable 24/h video streaming access to the baby, nurse contact, and contactless expressed milk delivery services have potential in high-equipped settings [7¹¹]. However, policies that ensure families have access to their infant for skin-to-skin care during the pandemic remain an essential first step in many institutions.

Isolating mothers is not the answer for future outbreaks or pandemics. Although digital health-care is likely to remain critical, in-person support will always remain paramount for breastfeeding mothers needing assistance during the early days and a sense of connection for wellbeing. Small support bubbles or groups can be established that enable the mother and caregiver confidence in accessing health services and mothers' groups, such as rapid COVID-19 antigen testing, vaccination requirements, and standardized hygiene practices. Although these practices may have already

informally introduced in many countries, limited legislation supports new mothers, specifically during the pandemic.

Finally, although not unique to the pandemic, ensuring that women have access to comprehensive wellbeing services is vital [7¹¹]. Lactation care clearly must be linked to relevant support that includes mental wellbeing and social welfare, including services that assist with financial stability, job opportunities, and childcare [7¹¹]. Similarly, having access to paid maternity and family leave adaptable in times of lock-downs and self-isolation may assist families' wellbeing and enable the continuation of breastfeeding.

CONCLUSION

The COVID-19 pandemic has highlighted and increased the disparities new mothers already face during birth, after-care, and when establishing lactation. Breastfeeding during the pandemic remains an essential public health priority to ensure optimal health outcomes and possible protection from the virus of all infants and children. Prioritizing mental health and adaptable lactation care, including

digital and face-to-face services and support, will help ensure that women can continue breastfeeding now and into the future of the pandemic.

Acknowledgements

None.

Financial support and sponsorship

The present research was funded by an unrestricted research grant from Medela AG (Switzerland).

Conflicts of interest

D.T.G and S.L.P. receive funding from an unrestricted research grant from Medela AG, administered by the University of Western Australia

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Merewood A, Davanzo R, Haas-Kogan M, *et al.* Breastfeeding supportive practices in European hospitals during the COVID-19 pandemic. *J Matern -Fetal Neonatal Med* 2021; 1–7.

A survey of health professionals in Europe highlighted that women were consistently discharged early from hospital after birth during the pandemic. The earlier discharge may have resulted in poorer postnatal care for these women. Policies also led to reductions in family visitations in neonatal intensive care settings.

2. Semaan A, Audet C, Huysmans E, *et al.* Voices from the frontline: findings from a thematic analysis of a rapid online global survey of maternal and newborn health professionals facing the COVID-19 pandemic. *BMJ Glob Health* 2020; 5:e002967.

A survey of health professionals in maternal and newborn services highlights the consistent changes in delivery and hospitals across 81 countries. There were widespread reductions in routine maternity care services used in high and low- and middle-income countries, which were not all evidence-based changes.

3. Coxon K, Turienzo CF, Kweekel L, *et al.* The impact of the coronavirus (COVID-19) pandemic on maternity care in Europe. *Midwifery* 2020; 88:102779.

4. Spatz DL, Davanzo R, Miller JA, *et al.* Promoting and Protecting Human Milk and Breastfeeding in a COVID-19 World. *Front Pediatr* 2021; 8:1000.

This review provides evidence of lactation and breastfeeding recommendations during the COVID-19 pandemic.

5. Dimopoulou D, Triantafyllidou P, Daskalaki A, *et al.* Breastfeeding during the novel coronavirus (COVID-19) pandemic: guidelines and challenges. *J Matern Fetal Neonatal Med* 2020; 1–7.

6. Snyder K, Worlton G. Social support during COVID-19: perspectives of breastfeeding mothers. *Breastfeed Med* 2021; 16:39–45.

7. Singh AP, Kumar VH, Panda S. Supporting breastfeeding in 2021 and beyond—lessons from the pandemic. *Pediatr Rep* 2021; 13:289–301.

This review provides a timeline of breastfeeding and maternity recommendations and services changes during the pandemic. It offers insightful and futuristic models for lactation and perinatal care during and after the pandemic.

8. UNICEF. Breastfeeding during the COVID-19 pandemic; 2020. Available at: <https://www.unicef.org/eap/breastfeeding-during-covid-19> [cited November 10, 2021].

9. WHO. Breastfeeding and COVID-19. Available at: <https://www.who.int/publications/i/item/10665332639> [cited November 10, 2021].

10. American Academy of Pediatrics. FAQs: management of infants born to mothers with suspected or confirmed COVID-19. Available at: <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/faqs-management-of-infants-born-to-covid-19-mothers> [cited October 15, 2021].

11. Salvatore CM, Han J-Y, Acker KP, *et al.* Neonatal management and outcomes during the COVID-19 pandemic: an observational cohort study. *Lancet Child Adolesc* 2020; 4:721–727.

The observational study demonstrates that when public health hygiene measures are followed, SARS-CoV-2 positive mothers are at low risk of transmitting the virus when rooming-in and breastfeeding in the hospital.

12. Gale C, Quigley MA, Placzek A, *et al.* Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance. *Lancet Child Adolesc* 2021; 5:113–121.

13. Shlomai NO, Kasirer Y, Strauss T, *et al.* Neonatal SARS-CoV-2 infections in breastfeeding mothers. *Pediatrics* 2021; 147:e2020010918.

14. Adhikari EH, Moreno W, Zofkie AC, *et al.* Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection. *JAMA Netw Open* 2020; 3:e2029256.

15. Zambrano LD, Ellington S, Strid P, *et al.* Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status – United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:1641–1647.

Analysis of 400 000 women aged 15–44 years with symptomatic SARS-CoV-2 demonstrated they are more likely to be admitted to intensive care, be mechanically ventilated, and have a higher risk of death than nonpregnant women. This study suggests pregnant women should be counselled on their increased risk and seek medical care immediately if experiencing symptoms of COVID-19.

16. Villar J, Ariff S, Gunier RB, *et al.* Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTER-COVID multinational cohort study. *JAMA Pediatr* 2021; 175:817–826.

A cohort study across 43 institutions and 18 countries assessed the risks associated with SARS-CoV-2 during pregnancy compared to nonpregnant women. Infection during pregnancy was associated with significant increases in maternal and neonatal morbidity and mortality compared to nonpregnant women.

17. Dumitriu D, Emeruwa UN, Hanft E, *et al.* Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. *JAMA Pediatr* 2020; 175:157–167.

18. Muhidin S, Behboodi Moghadam Z, Vizheh M. Analysis of maternal coronavirus infections and neonates born to mothers with 2019-nCoV; a systematic review. *Arch Acad Emerg Med* 2020; 8:e49–e149.

19. Zeng L, Xia S, Yuan W, *et al.* Neonatal early-onset Infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. *JAMA Pediatr* 2020; 174:722–725.

20. Piersigilli F, Carkeek K, Hocq C, *et al.* COVID-19 in a 26-week preterm neonate. *Lancet Child Adolesc* 2020; 4:476–478.

21. Vivanti AJ, Vauloup-Fellous C, Prevost S, *et al.* Transplacental transmission of SARS-CoV-2 infection. *Nat Commun* 2020; 11:3572.

22. Chambers C, Krogstad P, Bertrand K, *et al.* Evaluation for SARS-CoV-2 in breast milk from 18 infected women. *JAMA* 2020; 324:1347–1348.

This study tested human milk samples of symptomatic mothers with SARS-CoV-2 and showed no replication-competent SARS-CoV-2 viral RNA in a sample from a positive mother. Further, no cultural virus was measured following pasteurisation of samples spiked with viral RNA. This information suggested early in the pandemic that human milk is not a source of SARS-CoV-2 infection.

23. Groß R, Conzelmann C, Müller JA, *et al.* Detection of SARS-CoV-2 in human breastmilk. *Lancet* 2020; 395:1757–1758.

24. Costa S, Postero B, Marchetti S, *et al.* Excretion of SARS-CoV-2 in human breast milk. *Clin Microbiol Infect* 2020; 26:1430–1432.

25. Tam PCK, Ly KM, Kernich ML, *et al.* Detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19). *Clin Infect Dis* 2021; 72:128–130.

26. Wu Y, Liu C, Dong L, *et al.* Viral shedding of COVID-19 in pregnant women. *SSRN J* 2020.

27. Pace RM, Williams JE, Järvinen KM, *et al.* Characterization of SARS-CoV-2 RNA, antibodies, and neutralizing capacity in milk produced by women with COVID-19. *mBio*. 2021; 12:e03192–e3220.

The study tested human milk samples of SARS-CoV-2 positive mothers and showed that most samples contained SARS-CoV-2-specific IgA and IgG. The samples also demonstrated neutralising activity against SARS-CoV-2 *in vitro*, suggesting that infected mothers' milk contains beneficial and protective antibodies against SARS-CoV-2.

28. van Keulen BJ, Romijn M, Bondt A, *et al.* Human milk from previously COVID-19-infected mothers: the effect of pasteurization on specific antibodies and neutralization capacity. *Nutrients* 2021; 13:1645.

29. Fox A, Marino J, Amanat F, *et al.* Robust and specific secretory IgA against SARS-CoV-2 detected in human milk. *iScience* 2020; 23:101735.

This study sampled the human milk of SARS-CoV-2 positive and recovered women and found a dominant sIgA SARS-CoV-2 response in human milk after infection. IgG and IgM were also measured in milk samples.

30. Demers-Mathieu V, DaPraC MedoE. Comparison of severe acute respiratory syndrome coronavirus 2-specific antibodies' binding capacity between human milk and serum from coronavirus disease. *Recovered Women Breastfeed Med* 2021; 16:393–401.

31. Dan JM, Mateus J, Kato Y, *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021; 371:eabf4063.

32. Palmeira P, Carneiro-Sampaio M. Immunology of breast milk. *Rev Assoc Med Bras* 2016; 62:584–593.

33. Juncker HG, Romijn M, Loth VN, *et al.* Human milk antibodies against SARS-CoV-2: a longitudinal follow-up study. *J Hum Lact* 2021; 37:485–491. Longitudinal study shows that SARS-CoV-2 sIgA and IgG remain in human milk up to 5 months after the onset of SARS-CoV-2 symptoms. These data suggest that human milk offers passive immunity to the infant over this time.

34. Labayo HKM, Pajuelo MJ, Tohma K, *et al.* Norovirus-specific immunoglobulin A in breast milk for protection against norovirus-associated diarrhea among infants. *EClinical Medicine* 2020; 27:100561.
35. Schlaudecker EP, Steinhoff MC, Omer SB, *et al.* IgA and neutralizing antibodies to influenza A virus in human milk: a randomized trial of antenatal influenza immunization. *PLoS One* 2013; 8:e70867.
36. Conzelmann C, Groß R, Meister TL, *et al.* Pasteurization inactivates SARS-CoV-2-spiked breast milk. *Pediatrics* 2021; 147:e2020031690.
37. Minckas N, Medvedev MM, Adejuyigbe EA, *et al.* Preterm care during the COVID-19 pandemic: a comparative risk analysis of neonatal deaths averted by kangaroo mother care versus mortality due to SARS-CoV-2 infection. *EClinicalMedicine* 2021; 33:100733.
- Statistical modeling of 127 low-and middle-income countries adhering to complete coverage of kangaroo mother care and breastfeeding, and assuming a 100% transmission rate of COVID-19 would save 125 000 lives of neonates born <2000 g, compared to 1950 neonatal deaths because of SARS-CoV-2 infection. These data powerfully demonstrate the advantage of keeping mothers and infants together after birth and continued kangaroo mother care and breastfeeding in low and middle-income countries during the pandemic.
38. Adeyinka A, Bailey K, Pierre L, Kondamudi N. COVID 19 infection: pediatric perspectives. *J Am Coll Emerg Physicians Open* 2021; 2:e12375.
39. Juncker HG, Mulleners SJ, van Gils MJ, *et al.* The levels of SARS-CoV-2 specific antibodies in human milk following vaccination. *J Hum Lact* 2021; 37:477–484.
40. Perl SH, Uzan-Yulzari A, Klainer H, *et al.* SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. *JAMA* 2021; 325:2013–2014.
41. Gray KJ, Bordt EA, Atyeo C, *et al.* Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol* 2021; 225:303.e1-303.e17.
- The study followed pregnant, lactating, and nonpregnant controls after mRNA vaccination against SARS-CoV-2. They found both pregnant and lactating women demonstrated a robust immunological response with immune transfer occurring via the placenta and breastmilk.
42. Collier AY, McMahan K, Yu J, *et al.* Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. *JAMA* 2021; 325:2370–2380.
- The study followed pregnant, lactating, and nonpregnant controls after mRNA vaccination against SARS-CoV-2. They found both pregnant and lactating women exhibited binding and neutralizing antibodies in infant cord blood and human milk, respectively.
43. Romero Ramirez DS, Lara Perez MM, Carretero Perez M, *et al.* SARS-CoV-2 antibodies in breast milk after vaccination. *Pediatrics* 2021; 148:e2021052286.
44. Kelly JC, Carter EB, Raghuraman N, *et al.* Antisevere acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination. *Am J Obstet Gynecol* 2021; 225:101–103.
45. Kugelman N, Nahshon C, Shaked-Mishan P, *et al.* Maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at delivery after receipt of the BNT162b2 messenger RNA COVID-19 vaccine during the second trimester of pregnancy. *JAMA Pediatr* 2021; 21:e215683.
46. Bertrand K, Honerkamp-Smith G, Chambers CD. Maternal and child outcomes reported by breastfeeding women following messenger RNA COVID-19 vaccination. *Breastfeed Med* 2021; 16:697–701.
47. Shimabukuro TT, Kim SY, Myers TR, *et al.* Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. *N Engl J Med* 2021; 384:2273–2282.
48. Zauche LH, Wallace B, Smoots AN, *et al.* Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 vaccine pregnancy registry 2020-21. 2021
49. Ceulemans M, Hompes T, Foulon V. Mental health status of pregnant and breastfeeding women during the COVID-19 pandemic: a call for action. *Int J Gynaecol Obstet* 2020; 151:146–147.
50. Zanardo V, Manghina V, Giliberti L, *et al.* Psychological impact of COVID-19 quarantine measures in northeastern Italy on mothers in the immediate postpartum period. *Int J Gynaecol Obstet* 2020; 150:184–188.
51. Brown A, Shenker N. Experiences of breastfeeding during COVID-19: lessons for future practical and emotional support. *Matern Child Nutr* 2021; 17:e13088.
- This cross-sectional study assessed the experiences of UK-based pregnant and lactating women during the pandemic. They found that lockdowns were protective for continued breastfeeding amongst some women, whereas others cited that it directly contributed to their early weaning. Their data suggest that individual circumstances and the pandemic affect women differently, which should be considered in lactation and clinical care.
52. Davenport MH, Meyer S, Meah VL, *et al.* Moms are not OK: COVID-19 and maternal mental health. *Front Glob Womens Health* 2020; 1:1.
53. Guvenc G, Yesilcinar I, Ozkececi F, *et al.* Anxiety, depression, and knowledge level in postpartum women during the COVID-19 pandemic. *Perspect Psychiatr Care* 2020; 57:1449–1458.
54. Sakalidis VS, Rea A, Perrella SL, *et al.* Wellbeing of breastfeeding women in Australia and New Zealand during the COVID-19 pandemic: across-sectional study. *Nutrients* 2021; 13:1831.
55. Ceulemans M, Verbakel JY, van Calsteren K, an Eerdeken, *et al.* SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: results from an observational study in primary care in Belgium. *Int J Environ Res Public Health* 2020; 17:6766.
56. Hubschman-Shahar LE. Lactation telehealth in primary care: a systematic review. *Breastfeed Med* 2021; 17:6–21.